Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia-Reference-Cited by-同舟云学术

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

Published:2020-01-31 Issue:6477 Volume:367 Page:586-590
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Uckelmann Hannah J.¹²^ORCID,Kim Stephanie M.¹²^ORCID,Wong Eric M.¹²,Hatton Charles¹²^ORCID,Giovinazzo Hugh¹²,Gadrey Jayant Y.¹²^ORCID,Krivtsov Andrei V.¹²^ORCID,Rücker Frank G.³,Döhner Konstanze³,McGeehan Gerard M.⁴,Levine Ross L.⁵,Bullinger Lars⁶^ORCID,Vassiliou George S.⁷⁸^ORCID,Armstrong Scott A.¹²^ORCID

Affiliation:

1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston, MA, USA.

2. Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA.

3. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

4. Syndax Pharmaceuticals, Inc., Waltham, MA, USA.

5. Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

6. Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.

7. Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.

8. Wellcome Trust Sanger Institute, Cambridge, UK.

Abstract

Taking preventive measures Recent technological advances have made it possible to detect, in healthy individuals, premalignant blood cells that are likely to progress to hematologic cancer. These advances in early detection have fueled interest in “cancer interception,” the idea that drugs designed to treat advanced cancer might also be useful for cancer prevention. Uckelmann et al. now provide support for this concept in a study of mice genetically predisposed to develop acute myeloid leukemia. Early administration of an epigenetic therapy that had previously been shown to have anticancer activity in advanced leukemia models was able to eliminate preleukemia cells and extend survival of the mice. Science , this issue p. 586

Funder

National Institutes of Health

German research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference32 articles.

1. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

2. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

3. Genomic Classification and Prognosis in Acute Myeloid Leukemia

4. Acute Myeloid Leukemia

5. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation;Oncology and Therapy;2024-02-01

2. A new genomic framework to categorize pediatric acute myeloid leukemia;Nature Genetics;2024-01-11

3. Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?;International Journal of Molecular Sciences;2024-01-09

4. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

5. Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML;Biomarker Research;2023-12-05